Brovana is a brand name of arformoterol, approved by the FDA in the following formulation(s):
BROVANA (arformoterol tartrate - solution; inhalation)
Manufacturer: SUNOVION
Approval date: October 6, 2006
Strength(s): EQ 0.015MG BASE/2ML [RLD]
Has a generic version of Brovana been approved?
No. There is currently no therapeutically equivalent version of Brovana available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brovana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Patent 5,795,564
Issued: August 18, 1998
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor, Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased bronchial distribution when administered by inhalation.Patent expiration dates:
- April 3, 2012✓
- April 3, 2012
Formoterol process
Patent 6,040,344
Issued: March 21, 2000
Inventor(s): Gao; Yun & Hett; Robert & Fang; Kevin Q. & Wald; Stephen A. & Redmon; Martin P. & Senanayake; Chris Hugh
Assignee(s): Sepracor Inc.
A method is disclosed for the preparation of optically pure isomers of formoterol by the reaction of an optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-N-(phenylmethyl)benzeneethanamine followed by debenzylation. Useful intermediates in the process are also disclosed, as are the novel L-tartrate salt of R,R-formoterol and pharmaceutical compositions thereof.Patent expiration dates:
- November 12, 2016✓
- November 12, 2016
Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Patent 6,068,833
Issued: May 30, 2000
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.Patent expiration dates:
- April 3, 2012✓
- April 3, 2012
Formoterol tartrate process and polymorph
Patent 6,472,563
Issued: October 29, 2002
Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Patent expiration dates:
- November 9, 2021✓
- November 9, 2021
Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Patent 6,589,508
Issued: July 8, 2003
Inventor(s): Gunnar; Aberg & John; Morley
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.Patent expiration dates:
- April 3, 2012✓
- April 3, 2012
Formoterol tartrate polymorph
Patent 6,720,453
Issued: April 13, 2004
Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Patent expiration dates:
- November 9, 2021✓
- November 9, 2021
Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
Patent 6,866,839
Issued: March 15, 2005
Inventor(s): Aberg; Gunnar & Morley; John
Assignee(s): Sepracor Inc.
A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.Patent expiration dates:
- April 3, 2012✓
- April 3, 2012
Formoterol tartrate polymorph
Patent 7,145,036
Issued: December 5, 2006
Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
Assignee(s): Sepracor Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Patent expiration dates:
- November 9, 2021✓
- November 9, 2021
Formoterol tartrate process and polymorph
Patent 8,110,706
Issued: February 7, 2012
Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
Assignee(s): Sunovion Pharmaceuticals Inc.
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Patent expiration dates:
- November 9, 2021✓
- November 9, 2021
See also...
- Brovana Consumer Information (Drugs.com)
- Brovana Consumer Information (Wolters Kluwer)
- Brovana Consumer Information (Cerner Multum)
- Brovana Advanced Consumer Information (Micromedex)
- Brovana AHFS DI Monographs (ASHP)
- Arformoterol Consumer Information (Wolters Kluwer)
- Arformoterol inhalation Consumer Information (Cerner Multum)
- Arformoterol Inhalation Advanced Consumer Information (Micromedex)
- Arformoterol Tartrate AHFS DI Monographs (ASHP)
No comments:
Post a Comment